Theratechnologies Crecimiento futuro

Future controles de criterios 4/6

Se prevé un crecimiento anual de los beneficios y los ingresos de Theratechnologies de 64.6% y 17.4% respectivamente, mientras que el BPA crecerá en un 66.8% al año.

Información clave

64.6%

Tasa de crecimiento de los beneficios

66.8%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Biotechs	36.8%
Tasa de crecimiento de los ingresos	17.4%
Rentabilidad financiera futura	n/a
Cobertura de analistas	Low
Última actualización	03 Jun 2024

Actualizaciones recientes sobre el crecimiento futuro

Earnings Update: Theratechnologies Inc. (TSE:TH) Just Reported And Analysts Are Trimming Their Forecasts

Feb 24

Recent updates

Increases to CEO Compensation Might Be Put On Hold For Now at Theratechnologies Inc. (TSE:TH)

May 03

Theratechnologies Inc.'s (TSE:TH) Share Price Boosted 25% But Its Business Prospects Need A Lift Too

Apr 10

Earnings Update: Theratechnologies Inc. (TSE:TH) Just Reported And Analysts Are Trimming Their Forecasts

Feb 24

Investors Don't See Light At End Of Theratechnologies Inc.'s (TSE:TH) Tunnel And Push Stock Down 27%

Feb 07

The Market Doesn't Like What It Sees From Theratechnologies Inc.'s (TSE:TH) Revenues Yet

Apr 17

Previsiones de crecimiento de beneficios e ingresos

TSX:TH - Estimaciones futuras de los analistas y datos financieros pasados (USD Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
11/30/2026	113	22	32	30	4
11/30/2025	99	11	21	16	4
11/30/2024	88	0	6	-1	4
2/29/2024	78	-18	-6	-4	N/A
11/30/2023	82	-24	-7	-6	N/A
8/31/2023	80	-29	-7	-7	N/A
5/31/2023	80	-36	-16	-15	N/A
2/28/2023	81	-49	-14	-12	N/A
11/30/2022	80	-47	-16	-15	N/A
8/31/2022	77	-49	-19	-18	N/A
5/31/2022	74	-51	-19	-18	N/A
2/28/2022	73	-35	-18	-18	N/A
11/30/2021	70	-32	-18	-18	N/A
8/31/2021	70	-27	-15	-15	N/A
5/31/2021	66	-25	-12	-12	N/A
2/28/2021	66	-24	-14	-14	N/A
11/30/2020	66	-23	-14	-14	N/A
8/31/2020	63	-24	-11	-10	N/A
5/31/2020	65	-18	-5	-5	N/A
2/29/2020	64	-16	-13	-12	N/A
11/30/2019	63	-12	-7	-3	N/A
8/31/2019	61	-7	-21	2	N/A
5/31/2019	58	-5	-26	-3	N/A
2/28/2019	52	-4	-18	4	N/A
11/30/2018	45	-5	-19	0	N/A
8/31/2018	41	-7	-1	-1	N/A
5/31/2018	36	-9	-3	-3	N/A
2/28/2018	35	-15	0	0	N/A
11/30/2017	33	-14	N/A	2	N/A
8/31/2017	33	-11	N/A	3	N/A
5/31/2017	28	-8	N/A	3	N/A
2/28/2017	28	-1	N/A	4	N/A
11/30/2016	28	0	N/A	2	N/A
8/31/2016	27	1	N/A	2	N/A
5/31/2016	27	1	N/A	4	N/A
2/29/2016	25	2	N/A	5	N/A
11/30/2015	23	1	N/A	5	N/A
8/31/2015	18	-2	N/A	1	N/A
5/31/2015	12	-6	N/A	0	N/A
2/28/2015	8	-6	N/A	-4	N/A
11/30/2014	6	-9	N/A	-7	N/A
8/31/2014	5	-9	N/A	-6	N/A
5/31/2014	7	-7	N/A	-6	N/A
2/28/2014	7	-9	N/A	-6	N/A
11/30/2013	7	-4	N/A	-7	N/A
8/31/2013	10	-5	N/A	-10	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: Se prevé que TH sea rentable en los próximos 3 años, lo que se considera un crecimiento más rápido que la tasa de ahorro (2.1%).

Beneficios vs. Mercado: Se prevé que TH sea rentable en los próximos 3 años, lo que se considera un crecimiento del mercado superior a la media.

Beneficios de alto crecimiento: Se espera que TH sea rentable en los próximos 3 años.

Ingresos vs. Mercado: Se prevé que los ingresos (17.4% al año) de TH crezcan más rápidamente que los del mercado Canadian (7.3% al año).

Ingresos de alto crecimiento: Se prevé que los ingresos 17.4% al año) de TH crezcan más despacio que 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Datos insuficientes para determinar si la rentabilidad financiera de TH se prevé que sea elevada dentro de 3 años.

Theratechnologies Crecimiento futuro

Future controles de criterios 4/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Forecast to breakeven in 2024

Consensus EPS estimates upgraded to US$0.085 loss

Consensus estimates of losses per share improve by 70%

Theratechnologies Inc. Provides Earnings Guidance for the Fiscal Year 2024

Consensus EPS estimates fall by 12%

Earnings Update: Theratechnologies Inc. (TSE:TH) Just Reported And Analysts Are Trimming Their Forecasts

Recent updates

Forecast to breakeven in 2024

Consensus EPS estimates upgraded to US$0.085 loss

Theratechnologies Inc. Announces Frank Holler as Chair of the Board of Directors

Increases to CEO Compensation Might Be Put On Hold For Now at Theratechnologies Inc. (TSE:TH)

Consensus estimates of losses per share improve by 70%

First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Theratechnologies Inc. Provides Earnings Guidance for the Fiscal Year 2024

Theratechnologies Inc.'s (TSE:TH) Share Price Boosted 25% But Its Business Prospects Need A Lift Too

Theratechnologies Inc. Preclinical Data Presentation At AACR 2024 Highlights Versatility and Flexibility of SORT1+ Technology™ Oncology Platform

Theratechnologies Inc. Appoints Elina Tea to its Board of Directors and as Member of the Company's Audit Committee

Theratechnologies Inc. to Report Q1, 2024 Results on Apr 10, 2024

Theratechnologies Inc. Initiates Increased Dose Level in Phase 1 Clinical Trial of Sudocetaxel Zendusortide in Advanced Ovarian Cancer

Theratechnologies Inc., Annual General Meeting, May 09, 2024

Theratechnologies Inc. Announces Board Changes

Consensus EPS estimates fall by 12%

Earnings Update: Theratechnologies Inc. (TSE:TH) Just Reported And Analysts Are Trimming Their Forecasts

Price target increased by 300% to CA$8.00

Full year 2023 earnings: EPS and revenues miss analyst expectations

Theratechnologies Inc. Provides Earnings Guidance for the Year 2024

Theratechnologies Completes Enrollment of First Six Patients in Updated Phase 1 Clinical Trial of Sudocetaxel Zendusortide in Advanced Ovarian Cancer

Investors Don't See Light At End Of Theratechnologies Inc.'s (TSE:TH) Tunnel And Push Stock Down 27%

Theratechnologies Inc. to Report Q4, 2023 Results on Feb 21, 2024

Theratechnologies Inc. Receives Complete Response Letter (CRL) from the FDA for the F8 Formulation of Tesamorelin sBLA

Theratechnologies Inc. Announces FDA Approval of Trogarzo® 90-Second Intravenous (IV) Push Loading Dose

Soleus Capital Management Engages in Discussions with Theratechnologies

Theratechnologies Inc. announced that it has received $12.5 million in funding from Investissement Québec

Theratechnologies Inc. has completed a Follow-on Equity Offering in the amount of $12.5 million.

New major risk - Shareholder dilution

Theratechnologies Inc. announced that it expects to receive $12.5 million in funding from Investissement Québec

Theratechnologies Inc. announced that it expects to receive $12.5 million in funding from Investissement Québec

Theratechnologies Inc. Ibalizumab Demonstrates Cost-Effectiveness as an Addition to Routine Clinical Care in Heavily Treatment-Experienced People with HIV

Theratechnologies Inc. Presents Data at ID Week Showing Tesamorelin Reduces Visceral Adipose Tissue (VAT) and Liver Fat in People with HIV on Integrase Inhibitors (INSTIs)

Theratechnologies Announces Dosing of First Patient in Updated Clinical Trial of Sudocetaxel Zendusortide in Advanced Ovarian Cancer

Theratechnologies Inc. Receives January 2024 PDUFA Goal Date for Tesamorelin F8 Formulation sBLA

Third quarter 2023 earnings: EPS exceeds analyst expectations

Theratechnologies Submits Tesamorelin F8 Formulation Sbla for Fda Review

Theratechnologies Inc. to Report Q3, 2023 Results on Sep 26, 2023

Theratechnologies Inc. Announces All U.S. Oncology Clinical Sites Now Enrolling for Phase 1 Trial of Sudocetaxel Zendusortide

New minor risk - Share price stability

Theratechnologies Completes 1-For-4 Reverse Stock Split to Regain Compliance with Nasdaq Listing Requirements

Theratechnologies Inc. Announces Resignation of Gary Littlejohn as Board of Directors and Member of Its Audit Committee

Consensus EPS estimates fall by 37%

No longer forecast to breakeven

Theratechnologies Inc. Revises Revenue Guidance for the Fiscal Year of 2023

New major risk - Revenue and earnings growth

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

New minor risk - Profitability

Forecast to breakeven in 2025

Theratechnologies Inc. to Report Q2, 2023 Results on Jul 12, 2023

Price target decreased by 14% to CA$3.00

Theratechnologies Receives FDA Agreement to Amended Trial Protocol for Its Lead PDC Candidate Sudocetaxel Zendusortide

Theratechnologies Inc.'s Trogarzo® (Ibalizumab-uiyk) Shortens Time to HIV Undetectability and Extends Durability of Undetectability and Viral Suppression in a Matched Treatment Comparison

Consensus EPS estimates fall by 16%

The Market Doesn't Like What It Sees From Theratechnologies Inc.'s (TSE:TH) Revenues Yet

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Full year 2022 earnings: EPS misses analyst expectations

Theratechnologies Inc. Announces Path to Resume TH1902 Clinical Development

Theratechnologies Inc. to Report Q4, 2022 Results on Feb 28, 2023

Theratechnologies Inc. Provides Revenue Guidance for the Fiscal Year 2022 and Fiscal Year 2023

Theratechnologies Inc. Provides Revenue Guidance for the Fiscal Year 2022 and Fiscal Year 2023

Theratechnologies Inc Announces Update from Ongoing TH1902 Study

Theratechnologies Reports Data Showing High Expression of Sortilin (Sort1) in Multiple Solid Tumors from Tissue Microarrays

Theratechnologies Inc. Re-Affirms Revenue Guidance for the Fiscal Year of 2022

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Theratechnologies’ Trogarzo® Approved by Fda for 30-Second Intravenous (Iv) Push, Simplifying Hiv Treatment for Heavily Treatment-Experienced Population

Previsiones de crecimiento de beneficios e ingresos

Previsiones de crecimiento futuro de los analistas

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura